news

2024-11-13

PI3K-α inhibitor RP903 tablets have been approved for two additional PROS pediatric rare disease clinical trials.

Year:

2024-11-13

PI3K-α inhibitor RP903 tablets have been approved for two additional PROS pediatric rare disease clinical trials.

2024-11-13

Risen Pharma and Maiwei Biotech have signed a licensing agreement to jointly promote the development of drugs in the field of bone health.

2024-11-13

Risen Pharma has entered into a comprehensive strategic cooperation agreement with the Shanghai Center for Infectious Diseases and Immune Innovation.

2024-03-07

Risen's innovative KRAS drug research result has been selected for presentation at the AACR Annual Meeting 2024 in San Diego, California!

2023-12-20

Risen found status in the "2023 Hurun Global Cheetah Enterprise List"

2023-06-13

Congratulations! Risen successfully acquired Biosafety Laboratory level 2 (BSL-2) qualification.

Shanghai Zhangjiang R&D Center.

Suzhou Industrial Park R&D Center.